US20230398298A1 - Auto-Injector Device - Google Patents

Abstract

An injection device comprises an injector body having at least one indicator aperture; a medicament reservoir disposed within the injector body; a piston; and one or more status indicators. A movement of the piston expels a medicament out of the medicament reservoir, and operates to move at least one of the one or more status indicators relative to a corresponding indicator aperture.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
• The present application is a continuation of U.S. application Ser. No. 17/099,700, filed Nov. 16, 2020, which is a continuation of U.S. application Ser. No. 15/778,469, filed May 23, 2018, which is the national stage entry of International Patent Application No. PCT/EP2016/078245, filed on Nov. 21, 2016, and claims priority to Application No. EP 15196672.8, filed in on Nov. 27, 2015, the disclosures of which are incorporated herein by reference.
TECHNICAL FIELD
• The present disclosure relates to an auto-injector device.
BACKGROUND
• Injection devices, such as auto-injectors, are known in the art for dispensing a medicament to an injection site of a user. In particular, auto-injectors have been developed to enable laypersons to perform self-injections or injections on persons for which care is provided in a home care setting.
• An auto-injector can be held against the injection site of a user and automatically injects a medicament into an injection site of a patient. Mechanical auto-injectors comprise springs or other mechanisms as a mechanical energy storage which drives a mechanism for displacing the medicament out of the reservoir into the patient's injection site.
• Such injection devices can be needle based or needle free, and dispense the medicament when a trigger is activated. The trigger can be a button that is pressed by the user to start the injection. Alternatively, the trigger may be implemented as a depressible sleeve surrounding the needle or the medicament outlet, which sleeve is moved at least partly inside the injector housing when the user pushes the injector against the skin at the injection side. There are needle based injection devices in which the needle insertion into the patient's skin is performed manually by the user pressing the injection device against the skin at the injection site. In other injection device, the insertion of the needle into the skin takes place automatically as part of the injection automatic injection sequence.
• The injectable medicaments may be based on drug formulations which have viscosities higher than the viscosity of water. In some embodiments, medicaments of various viscosities can be injected. For example, viscosity could range from about 3 to about 50 cP. In other embodiments, viscosity could be less than about 3 cP or greater than about 50 cP. Injection can further include delivering a medicament to a sub-cutaneous, an intra-muscular, or a transdermal location within a patient's body. The medicament can be in the form of a liquid, gel, slurry, suspension, particle, powder, or other type. In some cases, the viscosity may be temperature dependent and decrease with rising temperature. For instance, formulations in the field of Biologics are known to have such properties.
• Devices of this type, as well as the medicament that they deliver, are commonly stored at relatively low ambient temperatures immediately before use. The medicament may, for example, be stored in a refrigerator at about 4° C. Injecting a liquid medicament at about 4° C. into the body can cause discomfort for the patient.
• Further, the drive mechanism in some auto-injector devices may have mechanical energy storages like pre-loaded springs or gas expansion based systems that change energy output based on their temperature. As described above, it may be a mechanical spring based mechanism. Alternatively, the drive mechanism may for instance include an electric motor and a gear mechanism that causes the piston to move for displacing the medicament into the user. Alternatively, the drive mechanism may be a gas or fluid pressure operated mechanism, in which case the piston driving energy source is either a reservoir of pressurised gas or a chemical system in which two or more chemicals are mixed together to produce gas or fluid pressure.
• The temperature dependent viscosity of the medicament or temperature dependent effects on the drive mechanism may change, e.g. prolong, the injection time significantly if the temperature is lower than prescribed, e.g., in cases where the user forgets to allow the injection to assume room temperature before performing the injection.
• If the auto-injector is removed before the delivery is complete the medicament dosage may be incorrect, therefore an auto-injector may include a window for the user to observe the injection progress and to verify that all of the medicament has been injected, or may provide a click sound when the delivery is complete. It may be difficult to observe the progress of the ongoing injection sequence or verify that all of the medicament has been dispensed if a chosen injection site requires holding the auto-injector at an angle from which the window is not observable, or if the user is visually or hearing impaired.
SUMMARY
• According to an aspect, an injection device is provided including an injector body having at least one indicator aperture, a medicament reservoir disposed within the injector body, a piston and one or more status indicators. A movement of the piston expels a medicament out of the medicament reservoir and operates to move at least one of the one or more status indicators relative to a corresponding indicator aperture.
• The injector body may have a longitudinal axis. The one or more status indicators may be pushed radially out of the injector body as the piston moves axially through the injector body.
• At least one of the status indicators may be positioned such that it is pushed out of the injector body when all or substantially all of the medicament has been propelled out of the medicament cartridge.
• One or more of the status indicators may be positioned to indicate that a predetermined amount of the piston movement is complete.
• The piston may include a stopper disposed in the medicament cartridge to expel the medicament, a piston shaft extending out of the medicament cartridge, and a piston head configured to push the one or more status indicators out of the injector body.
• The piston may include an actuating member which extends axially from the piston head. The actuating member may be arranged to be outside the medicament cartridge as the piston moves axially through the injector body.
• The position of one or more of the status indicators may be axially aligned with the medicament cartridge.
• Each status indicator may include a finger element which is pivotably mounted to extend radially into the injector body in a first position and to extend parallel to an internal surface of the injector body in a second position, and an elevated portion which projects from the finger element so as to pass through the corresponding indicator aperture when the finger element is in the second position. The movement of the piston may push the finger element from the first position to the second position.
• Each finger element may be formed by one or more cuts through an inner sleeve which is disposed internally within the injector body, with an uncut portion joining each finger element to the inner sleeve as a hinge.
• The status indicators may be formed from a flexible sheet which is deformed to bulge inwards into the interior of the injector body in a first position. The movement of the piston may push the flexible sheet to invert into a second position in which the flexible sheet is deformed to bulge outwards through the indicator aperture.
• The injection device may include a medicament which is retained within the medicament reservoir and is arranged to be expelled by the movement of the piston.
• One of the status indicators may be configured to produce an auditory signal or vibration when pushed through the at least one indicator aperture.
• An auto-injector is provided may include the injection device and a dispense mechanism configured to move the piston through the indicator body when activated.
• According to another aspect, a method of operating an injection device is provided, including moving a piston to expel a medicament out of a medicament reservoir in an injector body, and moving at least one of one or more status indicators relative to a corresponding indicator aperture in the injector body.
• These and other aspects of the invention will be apparent from and elucidated with reference to the embodiments described hereinafter.
BRIEF DESCRIPTION OF THE FIGURES
• Exemplary embodiments are described with reference to the accompanying drawings, in which:
• FIG.1A is a schematic side view of an injection device according to an exemplary embodiment, with a cap attached to a body of the injection device;
• FIG.1B is a schematic side view of the injection device ofFIG.1A, with the cap removed from the body;
• FIG.2 is a schematic cross-sectional side view of theFIGS.1A and1B injection device according to an exemplary embodiment;
• FIG.3 is a schematic cross-sectional side view of the injection device ofFIG.2;
• FIG.4 is a schematic cross-sectional side view of theFIGS.1A and1B injection device according to an exemplary embodiment; and
• FIG.5 is a schematic cross-sectional side view of theFIGS.1A and1B injection device according to an exemplary embodiment.
DETAILED DESCRIPTION
• An auto-injector device is provided which has a plurality of status indicators for indicating the current state of the injection process. The status indicators are located in apertures down the side of the injector body. The status indicators may be formed as finger elements which pivot within the apertures, or as a flexible sheet which is deformed to bulge through the apertures. In each embodiment, an element of each status indicator is forced outwards through the aperture by a piston of the syringe within the auto-injector as it dispenses the medicament.
• The outwardly forced status indicators are visible to the user and may be brightly coloured to provide clear feedback on the status of the auto-injector. In addition, the status indicators protrude from the body of the device and so provide tactile feedback, which improves usability for a user who may be visually impaired. Upon being pushed outwards, the status indicators may produce a click sound as a further auditory or vibrational feedback.
• A drug delivery device, as described herein, may be configured to inject a medicament into a patient. For example, delivery could be sub-cutaneous, intra-muscular, or intravenous. Such a device could be operated by a patient or care-giver, such as a nurse or physician, and can include various types of safety syringe, pen-injector, or auto-injector. The device can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 2 ml. Yet another device can include a large volume device (“LVD”) or patch pump, configured to adhere to a patient's skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large” volume of medicament (typically about 2 ml to about 5 ml).
• In combination with a specific medicament, the presently described devices may also be customized in order to operate within required specifications. For example, the device may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD). Other specifications can include a low or minimal level of discomfort, or to certain conditions related to human factors, shelf-life, expiry, biocompatibility, environmental considerations, etc. Such variations can arise due to various factors, such as, for example, a drug ranging in viscosity from about 3 cP to about 50 cP. Consequently, a drug delivery device will often include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 27 and 29 Gauge.
• The delivery devices described herein can also include one or more automated functions. For example, one or more of needle insertion, medicament injection, and needle retraction can be automated. Energy for one or more automation steps can be provided by one or more energy sources. Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy. One or more energy sources can be combined into a single device. Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device.
• The one or more automated functions of an auto-injector may each be activated via an activation mechanism. Such an activation mechanism can include one or more of a button, a lever, a needle sleeve, or other activation component. Activation of an automated function may be a one-step or multi-step process. That is, a user may need to activate one or more activation components in order to cause the automated function. For example, in a one-step process, a user may depress a needle sleeve against their body in order to cause injection of a medicament. Other devices may require a multi-step activation of an automated function. For example, a user may be required to depress a button and retract a needle shield in order to cause injection.
• In addition, activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence. For example, activation of a first automated function may activate at least two of needle insertion, medicament injection, and needle retraction. Some devices may also require a specific sequence of steps to cause the one or more automated functions to occur. Other devices may operate with a sequence of independent steps.
• Some delivery devices can include one or more functions of a safety syringe, pen-injector, or auto-injector. For example, a delivery device could include a mechanical energy source configured to automatically inject a medicament (as typically found in an auto-injector) and a dose setting mechanism (as typically found in a pen-injector).
• According to some embodiments of the present disclosure, an exemplarydrug delivery device10 is shown inFIGS.1A &1B.Device10, as described above, is configured to inject a medicament into a patient's body.Device10 includes ahousing11 which typically contains a reservoir containing the medicament to be injected (e.g., a syringe) and the components required to facilitate one or more steps of the delivery process.Device10 can also include acap assembly12 that can be detachably mounted to thehousing11. Typically a user must removecap12 fromhousing11 beforedevice10 can be operated.
• As shown,housing11 is substantially cylindrical and has a substantially constant diameter along the longitudinal axis X. Thehousing11 has adistal region20 and aproximal region21. The term “distal” refers to a location that is relatively closer to a site of injection, and the term “proximal” refers to a location that is relatively further away from the injection site.
• Device10 can also include aneedle sleeve13 coupled tohousing11 to permit movement ofsleeve13 relative tohousing11. For example,sleeve13 can move in a longitudinal direction parallel to longitudinal axis X. Specifically, movement ofsleeve13 in a proximal direction can permit a needle17 to extend fromdistal region20 ofhousing11.
• Insertion of needle17 can occur via several mechanisms. For example, needle17 may be fixedly located relative tohousing11 and initially be located within anextended needle sleeve13. Proximal movement ofsleeve13 by placing a distal end ofsleeve13 against a patient's body and movinghousing11 in a distal direction will uncover the distal end of needle17. Such relative movement allows the distal end of needle17 to extend into the patient's body. Such insertion is termed “manual” insertion as needle17 is manually inserted via the patient's manual movement ofhousing11 relative tosleeve13.
• Another form of insertion is “automated,” whereby needle17 moves relative tohousing11. Such insertion can be triggered by movement ofsleeve13 or by another form of activation, such as, for example, abutton22. As shown inFIGS.1A &1B,button22 is located at a proximal end ofhousing11. However, in other embodiments,button22 could be located on a side ofhousing11.
• Other manual or automated features can include drug injection or needle retraction, or both. Injection is the process by which a bung orpiston23 is moved from a proximal location within a syringe (not shown) to a more distal location within the syringe in order to force a medicament from the syringe through needle17. In some embodiments, a drive spring (not shown) is under compression beforedevice10 is activated. A proximal end of the drive spring can be fixed withinproximal region21 ofhousing11, and a distal end of the drive spring can be configured to apply a compressive force to a proximal surface ofpiston23. Following activation, at least part of the energy stored in the drive spring can be applied to the proximal surface ofpiston23. This compressive force can act onpiston23 to move it in a distal direction. Such distal movement acts to compress the liquid medicament within the syringe, forcing it out of needle17.
• Following injection, needle17 can be retracted withinsleeve13 orhousing11. Retraction can occur whensleeve13 moves distally as a user removesdevice10 from a patient's body. This can occur as needle17 remains fixedly located relative tohousing11. Once a distal end ofsleeve13 has moved past a distal end of needle17, and needle17 is covered,sleeve13 can be locked. Such locking can include locking any proximal movement ofsleeve13 relative tohousing11.
• Another form of needle retraction can occur if needle17 is moved relative tohousing11. Such movement can occur if the syringe withinhousing11 is moved in a proximal direction relative tohousing11. This proximal movement can be achieved by using a retraction spring (not shown), located indistal region20. A compressed retraction spring, when activated, can supply sufficient force to the syringe to move it in a proximal direction. Following sufficient retraction, any relative movement between needle17 andhousing11 can be locked with a locking mechanism. In addition,button22 or other components ofdevice10 can be locked as required.
• With reference toFIG.2, an auto-injector device100 according to an exemplary embodiment is shown. The auto-injector100 comprises anelongate injector body11 having amedicament cartridge18 disposed therein. The auto-injector may further comprise a needle (not shown) disposed at a distal end of themedicament cartridge18 and apiston140 disposed at the proximal end of themedicament cartridge18. The auto-injector device100 may further comprise a dispense button or sleeve trigger (not shown) and a dispense mechanism (not shown), substantially as described with respect toFIGS.1aand1b. The auto-injector device100 may alternatively be a needle free device comprising an outlet nozzle (not shown).
• When auto-injector device100 is activated, the dispense mechanism causes thepiston140 to move axially towards the distal end of themedicament cartridge18. Thepiston140 according to the present embodiment comprises astopper141, apiston shaft142 and apiston head143. Thestopper141 is disposed within themedicament cartridge18 and has substantially the same cross-section diameter as an inner cross section diameter of themedicament cartridge18. Thestopper141 may be formed of a resilient rubber like material or may additionally have a rubber seal to improve contact and seal with the inner surface of themedicament cartridge18. As thestopper141 moves axially towards the distal end of themedicament cartridge18, a medicament16 within the cartridge is propelled or expelled out of themedicament cartridge18 through the needle or outlet nozzle.
• Thepiston shaft142 is arranged to connect thestopper141 at the distal end of thepiston140 and thepiston head143 at the proximal end of thepiston140. Thepiston shaft142 extends out of the proximal end of the medicament cartridge16. The cross-section of thepiston shaft142 has a smaller area than that of themedicament cartridge18 and thestopper141. Alternatively, thepiston140 has a constant cross section from thestopper141 to thepiston head143.
• Thepiston head143 is disposed at the proximal end of thepiston140 and has substantially the same cross section diameter as an inner cross section diameter of theinjector body11. In some embodiments, only a portion of thepiston head143, e.g. a portion comprised of one or more flanges, extends from thepiston shaft142 toward the inner surface of theinjector body11.
• The auto-injector100 comprises a plurality ofstatus indicators120 arranged in one or more rows along the length of theinjector body11. Thestatus indicators120 are pivotably mounted to theinjector body11 so as to extend radially towards the interior of the injector body in a first position and lie flat against the interior surface of theinjector body11 in a second position. Theinjector body11 is formed to have anindicator aperture111 corresponding to each of the plurality of status indicators, wherein a portion of thestatus indicator120 extends through theindicator aperture111 to the exterior of theinjector body11 when the status indicator is in the second position. Thestatus indicators120 are arranged axially between a proximal point which is aligned with thepiston head143 before the auto-injector100 is activated and a distal point which is aligned with thepiston head143 when the injection is completed.
• Thestatus indicators120 according to the first embodiment comprise afinger element121 attached to theinjector body11 by means of a hinge, which extends at an angle towards the interior of the injector body in a first position and extends parallel to the interior surface of the injector body in a second position. Anelevated portion122 projects from eachfinger element121 and extends radially outwards through theindicator aperture111 when thestatus indicator120 is in the second position. Theelevated portions122 of the plurality ofstatus indicators120 may be a different colour to the external surface of theinjector body11.
• The plurality ofstatus indicators120 further comprise connecting means in the form of aninner sleeve123, which is a cylindrical structure arranged to fit inside theinjector body11 and lie flat against the interior surface of theinjector body11. The plurality offinger elements121 are formed as part of theinner sleeve123, for example, by cutting around eachfinger element121 through a sheet material which forms the sleeve. A portion of the sheet material is left to form a hinge joining eachfinger element121 to theinner sleeve123, which is coupled to the interior surface of theinjector body11. Theinner sleeve123 is positioned such that the plurality offinger elements121 and the correspondingelevated portion122 for eachfinger element121 is aligned with acorresponding indicator aperture111.
• The movement of thepiston head143 axially through theinjector body11 presses the plurality ofstatus indicators120 to lie flat against the interior surface of theinjector body11 in the second position. A leading edge of thepiston head143 is shaped to engage with thestatus indicators120 and move thestatus indicators120 from the first position to the second position. As eachstatus indicator120 is moved into the second position by the passage of thepiston head143, theelevated portion122 of thestatus indicator120 is moved radially out of theinjector body11 through thecorresponding indicator aperture111.
• When auto-injector device100 is activated, the dispense mechanism causes thepiston140 to move axially through theinjector body11 and thepiston head143 engages with each of thestatus indicators120 arranged in a row in turn. Accordingly, as thepiston head143 progresses axially through theinjector body11, thestatus indicators120 are moved in turn from the first position to the second position. As the medicament16 is delivered by the dispense mechanism, the plurality ofstatus indicators120 are moved into the second position, such that theelevated portion122 of eachstatus indicator120 extends out of theinjector body11. Here, there are two or more rows consisting of threestatus indicators120.
• Thestatus indicators120 indicate the position of thepiston head143 as it moves axially through theinjector body11. Theelevated portion122 of eachstatus indicator120 is urged through thecorresponding indicator aperture111 when thepiston head143 passes behind that status indicator. The status indicators provide visual feedback for the user as they can be seen protruding from the outer surface of theinjector body11 and they can provide a contrasting colour element when activated. Thestatus indicators120 further provide tactile feedback as they can be felt by the user when they are protruding from the outer surface of theindicator body11. In addition, thestatus indicators120 may further comprising clicking means (not shown) configured to produce an auditory or vibrational signal when thestatus indicators120 are moved into the second position.
• With reference toFIG.3, the auto-injector100 of the first embodiment is shown in an activated state. The axial movement of thepiston140 through themedicament cartridge18 is completed, and so delivery of the medicament16 through the needle or outlet nozzle is complete. The threestatus indicators120 in each row represent the progress on the injection when the dispense mechanism of the auto-injector100 has been activated. Proceeding from the proximal end of a row ofstatus indicators120, afirst status indicator120ais arranged such that it is moved from the first position to the second position immediately upon activation of the dispense mechanism, by the first axial movement of thepiston head143. Thefirst status indicator120aprovides feedback to the user that the dispense mechanism has been activated successfully and the injection is in progress.
• Asecond status indicator120bis positioned to indicate a halfway point in the injection process. Thesecond status indicator120bis arranged such that thepiston head143 passes thefinger element121 of thestatus indicator120bwhen half of the medicament has been delivered. Thesecond status indicator120bprovides feedback to the user that the dispense mechanism is working correctly and the medicament16 is being delivered normally.
• Athird status indicator120cis positioned to indicate completion of the injection, as shown inFIG.3. When thestopper141 of thepiston140 is located at the distal end of themedicament cartridge18, thepiston head143 is positioned to move thefinger element121 of thethird status indicator120cto the second position. Thethird status indicator120cprovides feedback to the user that all of the medicament16 has been dispensed from themedicament cartridge18 and it is therefore safe to remove the needle from the injection site. In some embodiments, astatus indicator120cfor indicating completion may be distinguished fromother status indicators120 by, for example, a different colour, a different shape ofelevated portion122, or a greater extent of protrusion from theinjector body11.
• According to the first embodiment shown inFIG.3, the plurality ofstatus indicators120 are configured to remain in the second position after being moved from the first position by thepiston140. Thefinger element121 of eachstatus indicator120 may be held in position by a holding or locking mechanism or, alternatively, by a friction fit against theinner sleeve123 orindicator aperture111.
• An auto-injector200 according to a second embodiment is depicted inFIG.4. According to the second embodiment, eachstatus indicator220 further comprises a biasing means which returns thefinger element221 from the second position to the first position in the absence of a force from thepiston140. As such, eachstatus indicator220 returns to the first position after thepiston head143 has moved axially past thestatus indicator220. The completion of the injection is indicated by the protrusion of theelevated portion222 of thethird status indicator220conly.
• An auto-injector300 according to a third embodiment is depicted inFIG.5. According to the third embodiment, thepiston340 comprises astopper341, apiston shaft342 and apiston head343, substantially as described with respect to the first embodiment, and further comprises an actuatingmember344 which extends axially from thepiston head343 in a distal direction.
• The actuatingmember344 is formed as a cylindrical outer sleeve having an outer diameter which is the same as the outer diameter of thepiston head343. That is, the outer diameter of the actuatingmember344 us the same is the inner diameter of theinner sleeve323 of the plurality ofstatus indicators320.
• The actuatingmember344 is arranged to extend in a distal direction from the leading edge of thepiston head343 between thehousing11 and themedicament chamber18. The actuatingmember344 forms a cylindrical sleeve disposed adjacent to the outer surface of themedicament chamber18, and adjacent to the inner surface of theinner sleeve323.
• Theindicators320 are arranged axially between a proximal point which is aligned with the distal end of the actuatingmember344 before the auto-injector300 is activated and a distal point which is aligned with the distal end of the actuatingmember344 when the injection is completed.
• The movement of the actuatingmember344 together with thepiston340 axially through theinjector body11 presses the plurality ofstatus indicators320 to lie flat against the interior surface of theinjector body11 in the second position. A leading edge of the actuatingmember344 is shaped to engage with thestatus indicators320 and move thestatus indicators320 from the first position to the second position. As eachstatus indicator320 is moved into the second position by the passage of the actuatingmember344, theelevated portion322 of thestatus indicator320 is moved radially out of theinjector body11 through thecorresponding indicator aperture111.
• When auto-injector device300 is activated, the dispense mechanism causes thepiston340 and the actuatingmember344 to move axially through theinjector body11 and the actuatingmember344 engages with each of thestatus indicators320 arranged in a row in turn. Accordingly, as the actuatingmember344 progresses axially through theinjector body11, thestatus indicators320 are moved in turn from the first position to the second position. As the medicament16 is delivered by the dispense mechanism, the plurality ofstatus indicators320 are moved into the second position, such that theelevated portion322 of eachstatus indicator120 extends out of theinjector body11. Here, there are two or more rows consisting of threestatus indicators320.
• Thestatus indicators320 indicate the position of the actuatingmember344 as it moves axially through theinjector body11. Theelevated portion322 of eachstatus indicator320 is urged through thecorresponding indicator aperture111 when the actuatingmember344 passes behind that status indicator. The status indicators provide visual feedback for the user as they can be seen protruding from the outer surface of theinjector body11 and they can provide a contrasting colour element when activated. Thestatus indicators120 further provide tactile feedback as they can be felt by the user when they are protruding from the outer surface of theindicator body11.
• Theindicators320 are disposed at least partly alongside the medicament reservoir, and so a user can receive feedback when grasping the auto-injector device300 at a point which is closer to the distal end of the device. This positioning is preferable to reduce the potential lever length, and hence, reduce the likelihood of moving the auto-injector device relative to the skin. Such movement may cause pain as it causes a sideways movement of the needle inside the skin. With theindicators320 disposed at the distal end of the device, the user is able to receive tactile feedback from theindicators320 during and at the end of the injection while holding the device in a stable position.
• In an alternative embodiment, the actuating member may be formed to include an aperture or a cutaway such that only the distal end of the actuating member engages with the status indicators and the actuating member engaged with only one of the status indicators at a time. As described with respect to the second embodiment, each status indicator may comprise a biasing means which returns the finger element from the second position to the first position in the absence of a force from the actuating member. As such, each status indicator returns to the first position after the distal end of the actuating member has moved axially past the status indicator. The completion of the injection is indicated protrusion of the elevated portion of the third status indicator only.
• An auto-injector according to a fourth embodiment (not shown) comprises a plurality of status indicators arranged in one or more rows along the length of the injector body. The one or more status indicators each comprise a flexible sheet disposed at the corresponding indicator aperture, wherein the flexible sheet extends over the aperture. The flexible sheet is deformed to form a concave structure which extends into the interior of the injector body.
• In some embodiments, the plurality of status indicators may be formed from an inner sleeve, which is a single flexible sheet formed into a cylinder to fit inside the injector body and lie flat against the interior surface of the injector body. Each status indicator is formed by a deformed area of the inner sleeve located at a corresponding indicator aperture.
• The flexible sheet is in a first position when it is bulged inwards to protrude into the interior of the injector body, and can be inverted into a second position wherein it is bulged outwards to protrude out of the injector body through the indicator aperture. The flexible sheet forms a convex structure which extends out of the injector body when it is inverted into the second position.
• When auto-injector device is activated, the dispense mechanism causes the piston to move axially through the injector body and the piston head engages with each of the status indicators arranged in a row in turn. Accordingly, as the piston head progresses axially through the injector body, the flexible sheet of each status indicator in turn is inverted from the first position to the second position. As the medicament is delivered by the dispense mechanism, the plurality of status indicators are moved into the second position, such that the flexible sheet of each status indicator forms a convex structure which extends out of the injector body.
• The status indicators of the fourth embodiment indicate the passage of the piston head as it moves axially through the injector body. The flexible sheet of each status indicator is urged to invert through the corresponding indicator aperture when the piston head passes behind that status indicator. The status indicators provide visual feedback for the user as they can be seen protruding from the outer surface of the injector body and they can provide a contrasting colour element when activated. The status indicators further provide tactile feedback as they can be felt by the user when they are protruding from the outer surface of the indicator body. In addition, the status indicators may further comprising clicking means configured to produce an auditory or vibrational signal when the status indicators are moved into the second position.
• Although a few embodiments have been shown and described, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the disclosure, the scope of which is defined in the appended claims. Various components of different embodiments may be combined where the principles underlying the embodiments are compatible. For example, in some embodiments, a single status indicator may be arranged to provide feedback that the dispense process has started or is completed. Alternatively, a plurality of status indicators may be arranged in one or more rows, or may be distributed around the surface of the indicator body in a regular pattern or with an irregular spacing. In some embodiments, the status indicators may comprise a finger element attached directly to the injector body to lie within the indicator aperture.
• The dispense mechanism of an embodiment may be any suitable dispense mechanism. In some embodiments, the dispense mechanism includes a dispense button which activates a driving element to drive the rubber stopper through the medicament reservoir. The driving element may be, for example, a compressed coil spring, a compressed gas source, or an electric motor. The dispense mechanism may be a needle-less arrangement, which is configured to squirt a fine jet of liquid medicament at sufficient pressure to penetrate the skin at the injection site. The dispense mechanism may include a compressed gas source configured to expel the liquid medicament at a high pressure. The dispense mechanism may be activated automatically upon pushing a retractable sleeve completely into the housing, that is, by pressing the device against an injection site of the user.
• In an alternative embodiment, an injection device is provided which is a manual injection device such as, for example, a syringe. A piston is pushed into the syringe by a user to expel a medicament through a needle at the distal end of the syringe. A plurality of status indicators, substantially as described with respect to the first embodiment or the second embodiment, are pushed into an activated position by the axial movement of the piston.
• The terms “drug” or “medicament” are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier. An active pharmaceutical ingredient (“API”), in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.
• As described below, a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Examples of API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
• The term “drug delivery device” shall encompass any type of device or system configured to dispense a drug or medicament into a human or animal body. Without limitation, a drug delivery device may be an injection device (e.g., syringe, pen injector, auto injector, large-volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal or pulmonary), an implantable device (e.g., drug- or API-coated stent, capsule), or a feeding system for the gastro-intestinal tract. The presently described drugs may be particularly useful with injection devices that include a needle, e.g., a hypodermic needle for example having a Gauge number of 24 or higher.
• The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20° C.), or refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and/or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
• The drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and/or prophylaxis of many different types of medical disorders. Examples of disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis. Examples of APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.
• Examples of APIs for the treatment and/or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms “analogue” and “derivative” refer to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness). In particular, the term “analogue” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring peptide and/or by adding at least one amino acid residue. The added and/or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogues are also referred to as “insulin receptor ligands”. In particular, the term “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g. a fatty acid) is bound to one or more of the amino acids. Optionally, one or more amino acids occurring in the naturally occurring peptide may have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable, have been added to the naturally occurring peptide.
• Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
• Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N—(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyhepta¬decanoyl) human insulin.
• Examples of GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®, Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Victoza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.
• An example of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.
• Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
• Examples of hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
• Examples of polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.
• The term “antibody”, as used herein, refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab′)2 fragments, which retain the ability to bind antigens. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix a complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. The term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).
• The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present disclosure include, for example, Fab fragments, F(ab′)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
• The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
• Examples of antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
• Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
• Those of skill in the art will understand that modifications (additions and/or removals) of various components of the APIs, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present disclosure, which encompass such modifications and any and all equivalents thereof.

Claims (20)

1. An injection device comprising:

an injector body;

a medicament reservoir disposed within the injector body; and

a piston configured to move through the injector body to expel a medicament out of the medicament reservoir and to sequentially activate a plurality of status indicators.

2. The injection device ofclaim 1, wherein the injector body has a longitudinal axis, and at least one status indicator of the plurality of status indicators is configured to be pushed radially out of the injector body as the piston moves axially through the injector body.

3. The injection device ofclaim 1, wherein at least one status indicator of the plurality of status indicators is positioned such that the at least one status indicator is to be moved when all or substantially all of the medicament has been propelled out of the medicament reservoir.

4. The injection device ofclaim 1, wherein at least one status indicator of the plurality of status indicators is positioned to indicate that a predetermined amount of the piston movement is complete.

5. The injection device ofclaim 1, wherein the piston comprises:

a stopper disposed in the medicament reservoir to expel the medicament;

a piston shaft extending out of the medicament reservoir; and

a piston head configured to push the one or more status indicators out of the injector body.

6. The injection device ofclaim 5, wherein the piston further comprises an actuating member that extends axially from the piston head, and wherein the actuating member is arranged to be outside of the medicament reservoir as the piston moves axially through the injector body.

7. The injection device ofclaim 6, wherein at least one status indicator of the plurality of status indicators is axially aligned with the medicament reservoir.

8. The injection device ofclaim 1, wherein at least one status indicator of the plurality of status indicators comprises:

a finger element that is pivotably mounted to extend radially into the injector body in a first position and to extend parallel to an internal surface of the injector body in a second position; and

an elevated portion that projects from the finger element so as to pass through an indicator aperture defined in the injector body when the finger element is in the second position,

wherein a movement of the piston pushes the finger element from the first position to the second position.

9. The injection device ofclaim 8, wherein the finger element is defined by one or more cuts through an inner sleeve that is disposed internally within the injector body, with an uncut portion of the inner sleeve joining the finger element to a cylindrical body of the inner sleeve as a hinge.

10. The injection device ofclaim 1, wherein each status indicator of the plurality of status indicators is defined by a flexible sheet that is deformed to provide the status indicator as an inner bulge that is directed radially inward into an interior region of the injector body in a first position of the status indicator, and wherein axial movement of the piston pushes the flexible sheet to invert the inner bulge into an outer bulge that passes through a respective indicator aperture of the injector body in a second position of the status indicator.

11. The injection device ofclaim 1, further comprising a medicament that is contained within the medicament reservoir and arranged to be expelled by movement of the piston.

12. The injection device ofclaim 1, wherein at least one status indicator of the plurality of status indicators is configured to produce an auditory signal or a vibration when pushed through the at least one indicator aperture.

13. An auto-injector comprising:

an injector body;

a medicament reservoir disposed within the injector body; and

a piston configured to move through the injector body to expel a medicament out of the medicament reservoir and to sequentially activate a plurality of status indicators.

14. The auto-injector ofclaim 13, wherein the injector body has a longitudinal axis, and at least one status indicator of the plurality of status indicators is configured to be pushed radially out of the injector body as the piston moves axially through the injector body.

15. The injection device ofclaim 13, wherein at least one status indicator of the plurality of status indicators is positioned such that the at least one status indicator is to be moved when all or substantially all of the medicament has been propelled out of the medicament reservoir.

16. The injection device ofclaim 13, wherein at least one status indicator of the plurality of status indicators is positioned to indicate that a predetermined amount of the piston movement is complete.

17. A method of operating an injection device, the injection device comprising an injector body, a medicament reservoir disposed within the injector body, a piston, and a plurality of status indicators, the method comprising:

moving the piston through the injector body to expel a medicament out of a medicament reservoir in an injector body and sequentially activating the plurality of status indicators.

18. The method ofclaim 17, wherein the injector body has a longitudinal axis, the method further comprising pushing at least one status indicator of the plurality of status indicators radially out of the injector body as the piston moves axially through the injector body.

19. The method ofclaim 17, further comprising moving at least one status indicator of the plurality of status indicators when all or substantially all of the medicament has been propelled out of the medicament reservoir.

20. The method ofclaim 17, further comprising indicating, by at least one status indicator of the plurality of status indicators, that a predetermined amount of the piston movement is complete.

Images